FDA approves Gleevec for children with acute lymphoblastic leukemia
The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 25, 2013 Category: American Health Source Type: news
Novartis Europharm Ltd withdraws marketing authorisation application for Ruvise (imatinib mesilate) for treatment of pulmonary arterial hypertension
Source: Eur Meds Agency
Area: News
The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for centralised marketing authorisation of Ruvise (imatinib mesilate) tablets, intended to be used for adults as add-on therapy for the treatment of pulmonary arterial hypertension (PAH). The company stated that it is withdrawing the application since additional data are required to address questions relating to the benefit-risk assessment of imatinib in PAH patients. These data will not be available within the timeframe allowed in the centralised procedure. (Sou...
Source: NeLM - Cardiovascular Medicine - January 25, 2013 Category: Cardiology Source Type: news
Surgery Improves Survival with GI Stromal Tumors
SAN FRANCISCO (MedPage Today) -- Imatinib therapy with surgical removal of residual tumors outperformed imatinib therapy alone for survival outcomes among patients with recurrent and metastatic gastrointestinal stromal tumors, researchers reported here. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 24, 2013 Category: Gastroenterology Source Type: news
Complete GIST Resection Increased With Prolonged Preoperative Imatinib
The use of imatinib mesylate preoperatively for a maximum of 12 months resulted in a high rate of complete microscopic resection in a group of patients with marginally resectable gastrointestinal stromal tumor (GIST), according to the results of a phase II trial. (Source: Cancer Network)
Source: Cancer Network - January 24, 2013 Category: Cancer & Oncology Source Type: news
Surgery Is Beneficial Even When GIST Responds to ImatinibSurgery Is Beneficial Even When GIST Responds to Imatinib
Patients with metastatic or recurrent gastrointestinal stromal tumors (GIST) had better survival when surgery was added to imatinib treatment. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Generic imatinib (Imatinib Teva) approved in the EU
Source: European Medicines Agency
Area: News
A generic imatinib product (Imatinib Teva) has been approved in the EU for the treatment of:
. Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
. Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
. Adult patients with Ph+ CML in blast crisis.
Imatinib Teva is a generic of Glivec®, which has bee...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
CHMP recommends approval of bosutinib (Bosulif®) for CML
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a conditional marketing authorisation for the orphan medicine bosutinib (Bosulif®) for the treatment of adults with Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Bosutinib is a protein kinase inhibitor that acts by inhibiting the abnormal Bcr-Abl kinase that promotes CML.
The positive...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
NCCN Announces Release of Gastrointestinal Stromal Tumors (GIST) Task Force Report
Hollywood, FL, March 11, 2004 – The National Comprehensive Cancer Network (NCCN) today introduces The NCCN Gastrointestinal Stromal Tumors (GIST) Task Force Report. The report, an expansion on The NCCN Sarcoma Clinical Practice Guidelines in Oncology, outlines the current thinking about the optimal management of patients with GIST. Though an uncommon cancer, GIST is increasingly recognized after experts reported that imatinib (Gleevec, Novartis Pharmaceuticals) an oral cancer therapy which tar... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 11, 2004 Category: Cancer & Oncology Source Type: news
